First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes
Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Triple Therapy in Type 1 Diabetes Improves Glycemic Control but Carries Ketosis Risks (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Adding dapagliflozin to liraglutide and insulin in patients with type 1 diabetes lowers hemoglobin A1c levels but poses risk for ketoacidosis, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 4, 2016 Category: Primary Care Source Type: news

Triple therapy helped type 1 patients improve glycemia
NEW ORLEANS – The addition of dapagliflozin to insulin and liraglutide in patients with type 1 diabetes resulted in a significant improvement in glycemia, results from a single-center randomized... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 13, 2016 Category: Endocrinology Source Type: news

Farxiga (Dapagliflozin Film-coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 28, 2016 Category: Drugs & Pharmacology Source Type: news

Xigduo XR (Dapagliflozin and Metformin HCl Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 27, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Strengthens Warnings on Two Diabetes Drugs (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM Two drugs used to treat type 2 diabetes — canagliflozin and dapagliflozin — are associated with an increased risk for acute kidney injury, cautions the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 15, 2016 Category: Primary Care Source Type: news

Canagliflozin, Dapagliflozin Warnings Strengthened by FDACanagliflozin, Dapagliflozin Warnings Strengthened by FDA
The FDA has strengthened its drug label warnings about the risk for acute kidney injury in patients taking canagliflozin or dapagliflozin for type 2 diabetes. News Alerts (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 15, 2016 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)
[6-14-2016] The U.S. Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 14, 2016 Category: Drugs & Pharmacology Source Type: news

AstraZeneca Combo for Type 2 Diabetes Gets Green Light in EUAstraZeneca Combo for Type 2 Diabetes Gets Green Light in EU
The EMA has given the green light to a fixed-dose combination of saxagliptin and dapagliflozin, the first combination of DPP-4/SGLT2 inhibitor in Europe, for the treatment of type 2 diabetes. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 27, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Dapagliflozin Plus Liraglutide and Insulin Effective in T1D (CME/CE)
(MedPage Today) -- But came with high risk of ketoacidosis, finds small study (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - May 27, 2016 Category: Journals (General) Source Type: news

ENDO: Farxiga Proves Effective in T1D, But Is it Safe? (CME/CE)
(MedPage Today) -- Risk of ketoacidosis when dapagliflozin added to liraglutide and insulin (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 5, 2016 Category: Consumer Health News Source Type: news

Sun Pharma to sell AstraZeneca's Type 2 diabetes medicine in India
Sun Pharmaceutical Industries has entered a partnership with AstraZeneca to sell the latter's Type 2 diabetes (T2D) medicine, dapagliflozin, in India. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 24, 2016 Category: Pharmaceuticals Source Type: news

Sun Pharma, AstraZeneca tie up to sell latest anti-diabetes drug Dapagliflozin
Diabetes estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 23, 2016 Category: Pharmaceuticals Source Type: news

Lau on Liraglutide: Is It Safe? AACE Video
NASHVILLE (MedPage Today) -- Exclusive AACE Video Conference Reporter coverage, with Hallway Takes from David C.W. Lau, PhD, on Liraglutide Safety; Shashank R. Joshi, MD, on the Saragliptin Trial; and Carolina Solis-Herrera, MD, on the Dapagliflozin Trial. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 18, 2015 Category: Cardiology Source Type: news

Three Diabetes Drugs Linked to Ketoacidosis, FDA Warns
(MedPage Today) -- FDA targets SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 16, 2015 Category: Cardiology Source Type: news